CytoMed Therapeutics Limited (GDTC) AI Stock Analysis

• Market Cap: $19.01M
• Dividend Yield: N/A
• Average Volume (3M): 166.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.08
• Revenue Growth: N/A
• EPS Growth: -21.99%
• Country: US
• Employees: 43
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 11,733,712
• 10 Day Avg. Volume: 104,297
• 30 Day Avg. Volume: 166,789
• PEG Ratio: 0.46
• Price to Book (P/B): 5.98
• Price to Sales (P/S): 754.46
• P/FCF Ratio: -13.04
• Enterprise Value/Market Cap: 1.27
• Enterprise Value/Revenue: 65.89
• Enterprise Value/Gross Profit: 63.51
• Enterprise Value/Ebitda: -9.44
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $2.00 ▲(26.58% Upside)

GDTC's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. Technical analysis further indicates bearish momentum, while valuation metrics highlight ongoing financial struggles with a negative P/E ratio and no dividend yield.

Positive Factors

Strategic Investment

The investment enhances CytoMed's financial stability and supports strategic growth in autologous therapies, strengthening its market position.

Market Expansion

Expanding into China with regulatory support can significantly increase market reach and revenue potential, enhancing long-term growth prospects.

Leadership Confidence

Increased insider ownership reflects confidence in the company's strategic direction and potential, positively impacting stakeholder trust.

Negative Factors

Financial Instability

Ongoing financial struggles with declining revenues and losses could hinder operational capabilities and long-term viability.

Negative Cash Flow

Negative cash flow indicates cash management issues, potentially limiting the ability to fund operations and growth initiatives.

Revenue Decline

Significant revenue decline suggests challenges in product adoption and market penetration, impacting future growth potential.

CytoMed Therapeutics Limited Business Overview & Revenue Model

Company Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

How the Company Makes Money

CytoMed Therapeutics generates revenue through multiple streams, including the commercialization of its proprietary therapies and technologies, licensing agreements with pharmaceutical companies, and partnerships with research institutions. The company may receive upfront payments, milestone payments based on the progress of clinical trials, and royalties on sales from licensed products. Additionally, funding from government grants and collaborations with industry partners contribute to its financial stability. Significant partnerships with key players in the biotech industry also enhance its research capabilities and market reach, thereby driving further revenue growth.

CytoMed Therapeutics Limited Financial Statement Overview

Summary

The company faces significant financial challenges, with declining revenues, persistent losses, and cash flow deficits. Despite a strong equity position relative to debt, the financial instability and poor profitability are concerning.

Income Statement

The income statement reveals significant challenges, with the company experiencing a decline in total revenue from $290,560 in 2023 to $52,005 in 2024, indicating a negative revenue growth rate. Additionally, the net income remained negative, with a considerable net loss of $1,883,178 in 2024, reflecting poor profitability and a concerning net profit margin.

Balance Sheet

The balance sheet shows a strong equity position with stockholders' equity significantly outweighing total debt, resulting in a low debt-to-equity ratio. However, the reduction in total assets and stockholders' equity from 2023 to 2024 highlights potential risks and financial instability.

Cash Flow

The cash flow statement indicates negative operating cash flow, with a substantial free cash flow deficit of $2,742,350 in 2024. While the company had a significant capital expenditure in 2024, the free cash flow remains negative, pointing to cash management challenges and the need for more efficient cash utilization.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	366.78K	52.01K	290.56K	0.00	84.18K	44.92K
Gross Profit	380.54K	52.38K	381.92K	-81.03K	81.59K	41.43K
EBITDA	-2.56M	-1.79M	-2.94M	-1.10M	-1.05M	-776.21K
Net Income	-3.35M	-1.88M	-3.13M	-2.27M	-1.53M	-1.47M
Balance Sheet
Total Assets	6.57M	7.37M	9.37M	3.90M	4.51M	2.89M
Cash, Cash Equivalents and Short-Term Investments	2.25M	3.64M	6.82M	1.18M	1.87M	703.20K
Total Debt	385.05K	339.20K	339.50K	3.15M	2.42M	2.26M
Total Liabilities	892.51K	749.76K	852.28K	3.46M	2.59M	2.53M
Stockholders Equity	5.62M	6.57M	8.52M	438.24K	1.92M	360.37K
Cash Flow
Free Cash Flow	-3.03M	-3.01M	-2.72M	-1.40M	-1.70M	-828.43K
Operating Cash Flow	-2.40M	-1.98M	-2.68M	-1.04M	-1.27M	-643.14K
Investing Cash Flow	2.79M	494.59K	-2.11M	-353.37K	-610.72K	-371.94K
Financing Cash Flow	-64.25K	-33.36K	8.16M	793.25K	3.09M	1.44M

CytoMed Therapeutics Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDTC, the sentiment is Negative. The current price of 1.58 is below the 20-day moving average (MA) of 1.75, below the 50-day MA of 2.01, and below the 200-day MA of 2.13, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 37.28 is Neutral, neither overbought nor oversold. The STOCH value of 16.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GDTC.

CytoMed Therapeutics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AKTX	44 Neutral	$8.27M	―	-196.60%	―	―	―
PASG	44 Neutral	$29.49M	-0.62	-87.18%	―	―	38.42%
GDTC	41 Neutral	$19.01M	-6.58	-42.29%	―	―	-21.99%
MTVA	33 Underperform	$18.72M	-0.55	-168.18%	―	―	71.57%
LPTX	31 Underperform	―	―	-196.76%	―	―	36.27%

CytoMed Therapeutics Limited Corporate Events

CytoMed Therapeutics Partners with Malaysian Hospital for Groundbreaking Cancer Trial

On December 8, 2025, CytoMed Therapeutics Limited announced a Memorandum of Understanding with Universiti Malaya Medical Centre in Malaysia to establish a multi-site, first-in-human Phase I clinical trial for its patented donor-derived gamma delta T cell product candidate. This trial aims to evaluate the safety and efficacy of these cells in cancer patients who have exhausted standard treatments. This collaboration is expected to provide an affordable immunotherapy option for patients with limited treatment alternatives, leveraging the natural ability of T cells to detect and kill cancer cells. The initiative complements CytoMed’s ongoing trials in Singapore and reflects its commitment to advancing clinical innovation in Southeast Asia.

CytoMed Therapeutics Finalizes Acquisition of T Cell Technology for Cancer Treatment in China and India

On November 18, 2025, CytoMed Therapeutics Limited announced the completion of its acquisition of TC BioPharm Limited’s gamma delta T cell technology, TCB-002, to enhance cancer treatment capabilities in China and India. This acquisition aligns with CytoMed’s strategy to establish a non-viral allogeneic gamma delta T cell immunotherapy platform. The technology, which has completed a Phase I clinical trial in Europe and received orphan drug designation by the FDA for Acute Myeloid Leukemia, will be adapted for use in China and India, leveraging new regulatory pathways and cost-effective manufacturing processes. This move replaces previous agreements with Chinese parties and positions CytoMed to capitalize on recent regulatory changes in China, potentially impacting its market positioning and stakeholder interests.

CytoMed Therapeutics Secures Investment and Advances China Strategy

On November 6, 2025, CytoMed Therapeutics announced securing a non-dilutive investment from ICH Capital for its subsidiary LongevityBank, which focuses on autologous therapies. The investment will help LongevityBank expand its personalized cellular banking services. Additionally, CytoMed is exploring a new strategy in China, leveraging recent regulatory changes to introduce its allogeneic gamma delta T cell platform. This strategic move is expected to enhance CytoMed’s market positioning in Southeast Asia and China, potentially benefiting stakeholders by expanding treatment options and improving accessibility to innovative cancer therapies.

CytoMed Therapeutics’ Chairman Boosts Stake Amid Biotherapeutics Growth

On October 22, 2025, CytoMed Therapeutics Limited announced that its Executive Chairman, Mr. Peter Choo, has increased his shareholding in the company by purchasing an additional 105,824 shares, bringing his total effective holdings to 21.95%. Mr. Choo’s decision reflects confidence in the company’s proprietary technologies and the growing interest in biotherapeutics in Asia, particularly in China. This move is seen as a strategic positioning within the expanding Southeast Asian healthcare market, which offers unique opportunities due to rising healthcare costs in the West and a supportive regulatory environment.

CytoMed Therapeutics Bids for TC BioPharm’s Assets Amid Strategic Expansion

On October 14, 2025, CytoMed Therapeutics Limited announced a cash bid for the acquisition of potentially synergistic assets from TC BioPharm Limited, which entered administration on October 2, 2025. This acquisition aims to enhance CytoMed’s expertise in allogeneic cell therapies for cancer treatment, potentially accelerating its commercialization timeline and expanding its mission to provide affordable therapeutic options globally. This move represents CytoMed’s second acquisition in a year, following its purchase of a licensed cord blood bank in Malaysia in 2024, which supports its strategic expansion into new therapeutics.

CytoMed Therapeutics Unveils Promising AML Therapy Research

On October 2, 2025, CytoMed Therapeutics Limited announced a significant advancement in their research collaboration with The University of Texas, MD Anderson Cancer Center. The publication of their preclinical study highlights the potential of CytoMed’s allogeneic γδ T cell therapy for treating acute myeloid leukemia (AML), marking a promising step forward in developing ‘off-the-shelf’ immunotherapy solutions. This development is expected to pave the way for further clinical trials in Southeast Asia, potentially offering new treatment options for patients with limited alternatives, thereby strengthening CytoMed’s position in the biopharmaceutical industry.

CytoMed Therapeutics Reports Increased Revenue Amidst Financial Challenges

On September 30, 2025, CytoMed Therapeutics Limited released its unaudited interim condensed consolidated financial statements for the six months ending June 30, 2025. The company reported a significant increase in revenue to S$155,887 compared to the previous year. However, the financial results also showed a comprehensive loss of S$2,269,263, reflecting ongoing challenges in the company’s financial performance. The announcement provides insights into the company’s operational challenges and financial health, which could impact its market positioning and stakeholder confidence.